|
|
Efficacy of Alzheimer treatment, hyperlipidemia, and acne treatment, drug side effects (APOE) |
PHGN |
|
|
Signs/symptoms: |
Efficacy of Alzheimer’s treatment, treatment of hyperlipidemia, 13-cis retin-acid treatment. |
|
Complications: |
Dementia, hyperlipidemia, acne. |
|
Early diagnosis/treatment: |
Yes |
|
|
|
Material required: |
|
Blood tubes: |
EDTA whole blood (do not freeze, do not centrifugate) |
|
Mouth brush: |
Yes |
|
|
|
|
|
Chromosomal localization: |
19q13.2 |
OMIM number: |
107741 |
|
|
|
Gene regions tested: |
|
Gene regions: |
|
E2/E3/E4-Variants |
|
Amino acid positions: |
C112R, R158C, R136S, A106V |
|
Nucleotide positions: |
|
|
Test methods: |
Restriction Fragment Length |
|
|
|
|
|
| 8820.00 |
8811.01 |
8818.00 |
|
|
8055.00 |
|
|
| |
TP REVAL: |
220 |
TP Value: |
0.9 |
CHF |
198.00 |
|
Other europe: |
EUR |
150.00 |
|
Other regions: |
USD |
call |
|
|
|
| Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J. 2006. | |
| Poirier J. Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease. Mol Diagn. 1999;4:335-341. | |
| Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther. 2006;11:211-221. | |
| Mooser V, Waterworth DM, Isenhour T, Middleton L. Cardiovascular pharmacogenetics in the SNP era. J Thromb Haemost. 2003;1:1398-402. | |
